HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Factor XI (Plasma Thromboplastin Antecedent)

Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.

Also Known As:

Plasma Thromboplastin Antecedent; Blood Coagulation Factor XI; Antecedent, Plasma Thromboplastin; Factor XI, Coagulation; Thromboplastin Antecedent, Plasma; XI, Coagulation Factor; Coagulation Factor XI; Blood-coagulation factor XI

Networked: 331 relevant articles (4 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gailani, David: 19 articles (04/2015 - 05/2002)
2.	Seligsohn, Uri: 10 articles (02/2011 - 04/2002)
3.	Salomon, Ophira: 9 articles (09/2013 - 06/2003)
4.	Tucker, Erik I: 8 articles (03/2014 - 07/2008)
5.	Renné, Thomas: 7 articles (09/2015 - 12/2007)
6.	Zivelin, Ariella: 7 articles (02/2011 - 04/2002)
7.	McCarty, Owen J T: 6 articles (03/2014 - 01/2009)
8.	Gruber, András: 6 articles (09/2012 - 07/2008)
9.	Glueck, Charles J: 5 articles (12/2015 - 10/2005)
10.	Wang, Ping: 5 articles (12/2015 - 10/2005)

Related Diseases

1.	Stroke (Strokes) 11/01/2015 - "Although there were weak positive associations between factor XI and total, ischemic, cardioembolic, and nonlacunar stroke, when adjusted for demographics, further adjustment for other stroke risk factors eliminated the associations. " 01/01/2013 - "Genetic variants of coagulation factor XI show association with ischemic stroke up to 70 years of age." 01/01/2010 - "Higher factor XI levels might help identify patients at elevated ischemic stroke risk." 01/01/2010 - "A greater level of factor XI was associated with an increased risk of ischemic stroke. " 11/01/2007 - "Higher risk of ischaemic stroke associated with factor XI levels in dyslipidaemic patients."
2.	Factor XI Deficiency (Hemophilia C) 07/01/2015 - "Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study." 06/15/2003 - "This study was undertaken to determine the prevalence of acquired inhibitors against factor XI in patients with severe factor XI deficiency, discern whether these inhibitors are related to specific mutations, and characterize their activity. " 10/01/1989 - "Cloning of abnormal factor XI genes and studies on the molecular genetics of factor XI deficiency show that the cause for factor XI deficiency is heterogeneous. " 08/01/1988 - "A study of 20 Jewish and four non-Jewish kindreds transmitting factor XI deficiency (164 individuals) confirmed inheritance to be autosomal with severe deficiency in homozygotes (mean factor XI level 3.8 u/dl, SD 2.91) and partial deficiency in heterozygotes (mean factor XI level 57 u/dl, SD 10.42; normal mean factor XI level 96 u/dl, SD 11.6). " 08/01/1984 - "[A study on platelet Factor XI-like activity in a family with congenital Factor XI deficiency]."
3.	Thrombosis (Thrombus) 07/01/2015 - "Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres." 01/15/2015 - "Making (anti)sense of factor XI in thrombosis." 11/01/2013 - "Coagulation factor XI (FXI) is a promising target for anticoagulation, because of its major role in thrombosis and relatively minor role in haemostasis. " 07/01/2013 - "Targeting factor XI to prevent thrombosis." 07/19/2012 - "Coagulation factor XI (FXI) plays an important part in both venous and arterial thrombosis, rendering FXIa a potential target for the development of antithrombotic therapy. "
4.	Inflammation 05/17/2012 - "Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis." 01/01/2012 - "Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis." 09/01/2008 - "This review focuses on articles, which report phenotypization of animals deficient in the contact system proteins factor XII, factor XI and high-molecular-weight kininogen, as well as novel links between factor XII and edema formation, discovery of new in-vivo activators of factor XII, and functions of the factor XII downstream protease factor XI. Recent studies improved understanding of the factor XII-driven contact system in hemostasis, thrombosis, and inflammation. " 03/01/1998 - "P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations."
5.	Edema 09/01/2008 - "This review focuses on articles, which report phenotypization of animals deficient in the contact system proteins factor XII, factor XI and high-molecular-weight kininogen, as well as novel links between factor XII and edema formation, discovery of new in-vivo activators of factor XII, and functions of the factor XII downstream protease factor XI. Recent studies improved understanding of the factor XII-driven contact system in hemostasis, thrombosis, and inflammation. " 10/01/1989 - "The clotting activity levels of factor XII, factor XI, plasma prekallikrein, and high-molecular-weight kininogen (HMWK) were measured, and plasma kallikrein-induced proteolytic cleavage of HMWK was assessed by ligand blotting by use of radiolabeled factor XI. After an ascent on foot from 1,170 to 4,559 m in 3 days, three subjects developed high-altitude pulmonary edema, and four subjects presented facial edema. "

Related Drugs and Biologics

1.	Factor XII (Hageman Factor)
2.	Proteins (Proteins, Gene)
3.	High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)
4.	Immunoglobulins (Immunoglobulin)
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	Prekallikrein
7.	Factor XI (Plasma Thromboplastin Antecedent)
8.	Factor IX (PTC)
9.	Antigens
10.	Antithrombin III

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Arthroplasty
3.	Catheters
4.	Bariatric Surgery
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)